

---

## Vemurafenib

产品编号: D51324

CAS: 918504-65-1

分子式: C<sub>23</sub>H<sub>18</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>3</sub>S

纯度: ≥98%

InChi: InChI=1S/C<sub>23</sub>H<sub>18</sub>ClF<sub>2</sub>N<sub>3</sub>O<sub>3</sub>S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-2  
3-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H<sub>2</sub>,1H<sub>3</sub>, (H,27,28)

InChi Key: GPXBXXGIAQBQNI-UHFFFAOYSA-N

Smiles: CCCS(=O)(=O)NC1C=CC(F)=C(C(=O)C2=CNC3=NC=C(C=C23)C2C=CC(Cl)=CC=2)C=1F

外观: 固体粉末

作用通路: Autophagy

溶解性: Soluble in DMSO, not in water

保存条件: Store in dry, dark place for one year.

产品介绍: Vemurafenib, also known as PLX4032, RG7204 or RO5185426, is an orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib received FDA approval for the treatment of late-stage melanoma on August 17, 2011. Vemurafenib selectively binds to the ATP-binding site of BRAF(V600E) kinase and inhibits its activity, which may result in an inhibition of an over-activated MAPK signaling pathway downstream in BRAF(V600E) kinase-expressing tumor cells and a reduction in tumor cell proliferation.